Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Q301 in Moderate to Severe Atopic Dermatitis
NCT02426359Phase 2Completed
- Sponsor
- Qurient Co., Ltd.
- Start
- Apr 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Q301 in atopic dermatitis (AD), sponsored by Qurient Co., Ltd.. Started Apr 2015; status: completed.
02
Drugs
Q301
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02426359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426359.